Randomized Trialhigh evidence
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
mAbs·December 1, 2026·PMID 42165327
Why it mattersProcizumab targets DPP3, a peptidase implicated in hemodynamic instability during cardiogenic shock. This study provides foundational human safety and pharmacokinetic data necessary to advance this first-in-class therapy into patient trials, where it may address an unmet need in shock management.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled